Zongertinib Demonstrates Clinical Promise in HER2-Mutated Non-Small Cell Lung Cancer

Clinical Summary: 

• Design/Population: The phase 1a/1b Beamion LUNG-1 trial evaluated zongertinib in previously untreated patients with advanced HER2-mutant NSCLC and an exploratory cohort of patients with active brain metastases.
• Key Outcomes: Zongertinib demonstrated high response rates, durable activity, and intracranial efficacy with manageable toxicity.
• Clinical Relevance: Zongertinib represents a potential first-line targeted therapy option for HER2-mutant NSCLC, including patients with active brain metastases.

According to results from the phase 1a/1b Beamion LUNG-1 trial, first-line zongertinib demonstrated sustained antitumor activity among patients with HER2-mutated non-small-cell lung cancer (NSCLC).

“Until recently, no first-line targeted treatment options were available for patients with [HER2]–mutant [NSCLC],” stated John Heymach, MD, PhD, MD Anderson Cancer Center, Houston, Texas, and coauthors. “Zongertinib is an oral, irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing wild-type EGFR, thereby minimizing associated toxic effects.”

In this multicohort study, 74 previously untreated patients with advanced or metastatic nonsquamous HER2-mutated NSCLC received 120 mg of once daily zongertinib. The primary end point was objective response. Key secondary end points included duration of response, progression-free survival (PFS), and safety. Exploratory end points included objective response and safety in patients with active brain metastases (n = 30). 

At analysis, 76% of patients achieved objective response. The median duration of response was 15.2 months and the median PFS was 14.4 months. Any-grade adverse events were reported in 99% of patients and grade ≥3 events were reported in 45% of patients. Treatment-related adverse events were reported in 91% of patients, including grade ≥3 treatment-related adverse events reported in 19% of patients. 

In the cohort of patients with active brain metastases, 47% of patients achieved intracranial objective response. Grade ≥3 treatment-related adverse events were reported in 17% of patients. 

“Zongertinib showed sustained efficacy in previously untreated patients with advanced or metastatic HER2-mutant NSCLC,” concluded Dr Heymach et al. “Treatment-related adverse events were predominantly low-grade.”

Source: 

Heymach JV, Yamamoto N, Girard N, et al. First-Line zongertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med. Published online: April 15, 2026. doi:10.1056/NEJMoa2516969